239 related articles for article (PubMed ID: 34725156)
1. Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation.
Liu X; Yang S; Hart JR; Xu Y; Zou X; Zhang H; Zhou Q; Xia T; Zhang Y; Yang D; Wang MW; Vogt PK
Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725156
[TBL] [Abstract][Full Text] [Related]
2. Structural and mechanistic insights provided by single particle cryo-EM analysis of phosphoinositide 3-kinase (PI3Kα).
Vogt PK; Hart JR; Yang S; Zhou Q; Yang D; Wang MW
Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188947. PubMed ID: 37394020
[TBL] [Abstract][Full Text] [Related]
3. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
[TBL] [Abstract][Full Text] [Related]
4. Nanobodies and chemical cross-links advance the structural and functional analysis of PI3Kα.
Hart JR; Liu X; Pan C; Liang A; Ueno L; Xu Y; Quezada A; Zou X; Yang S; Zhou Q; Schoonooghe S; Hassanzadeh-Ghassabeh G; Xia T; Shui W; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2210769119. PubMed ID: 36095215
[TBL] [Abstract][Full Text] [Related]
5. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Hon WC; Berndt A; Williams RL
Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
[TBL] [Abstract][Full Text] [Related]
6. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
[TBL] [Abstract][Full Text] [Related]
7. Structural insights into the activation mechanism of phosphoinositide 3-kinase alpha.
Jani V; Sonavane U; Sawant S
Comput Biol Chem; 2024 Feb; 108():107994. PubMed ID: 38043374
[TBL] [Abstract][Full Text] [Related]
8. Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.
Chen P; Deng YL; Bergqvist S; Falk MD; Liu W; Timofeevski S; Brooun A
Protein Sci; 2014 Oct; 23(10):1332-40. PubMed ID: 25043846
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into the interaction of three Y-shaped ligands with PI3Kα.
Zhou Q; Liu X; Neri D; Li W; Favalli N; Bassi G; Yang S; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2023 Aug; 120(34):e2304071120. PubMed ID: 37585458
[TBL] [Abstract][Full Text] [Related]
10. Double
Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J
Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of nSH2 regulation and lipid binding in PI3Kα.
Miller MS; Schmidt-Kittler O; Bolduc DM; Brower ET; Chaves-Moreira D; Allaire M; Kinzler KW; Jennings IG; Thompson PE; Cole PA; Amzel LM; Vogelstein B; Gabelli SB
Oncotarget; 2014 Jul; 5(14):5198-208. PubMed ID: 25105564
[TBL] [Abstract][Full Text] [Related]
12. Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects.
Gabelli SB; Echeverria I; Alexander M; Duong-Ly KC; Chaves-Moreira D; Brower ET; Vogelstein B; Amzel LM
Biophys Rev; 2014 Mar; 6(1):89-95. PubMed ID: 25309634
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.
Yu J; Wjasow C; Backer JM
J Biol Chem; 1998 Nov; 273(46):30199-203. PubMed ID: 9804776
[TBL] [Abstract][Full Text] [Related]
14. Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation.
Bian X; Dong W; Zhao Y; Sun R; Kong W; Li Y
J Mol Model; 2014 Apr; 20(4):2166. PubMed ID: 24633771
[TBL] [Abstract][Full Text] [Related]
15. Calmodulin (CaM) Activates PI3Kα by Targeting the "Soft" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α.
Zhang M; Li Z; Wang G; Jang H; Sacks DB; Zhang J; Gaponenko V; Nussinov R
J Phys Chem B; 2018 Dec; 122(49):11137-11146. PubMed ID: 30047727
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of the phosphoinositide 3-kinase p110δ interaction with p85α and membranes reveals aspects of regulation distinct from p110α.
Burke JE; Vadas O; Berndt A; Finegan T; Perisic O; Williams RL
Structure; 2011 Aug; 19(8):1127-37. PubMed ID: 21827948
[TBL] [Abstract][Full Text] [Related]
17. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition.
Maheshwari S; Miller MS; O'Meally R; Cole RN; Amzel LM; Gabelli SB
J Biol Chem; 2017 Aug; 292(33):13541-13550. PubMed ID: 28676499
[TBL] [Abstract][Full Text] [Related]
18. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
19. Allosteric Activation of PI3Kα Results in Dynamic Access to Catalytically Competent Conformations.
Chakrabarti M; Gabelli SB; Amzel LM
Structure; 2020 Apr; 28(4):465-474.e5. PubMed ID: 32049032
[TBL] [Abstract][Full Text] [Related]
20. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
